Acceleron To Be Next M&A Target With Rumored $11bn Deal
BMS Seen As Most Likely Suitor
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.